🔴 Connect Biopharma is trading 9.3% down today after asthma trial missed its primary endpoint

Connect Biopharma is trading 9.3% down at $1.12 after its Phase 2 asthma trial missed its primary 28-day treatment-failure endpoint.

• Continued selling followed the September 15 readout; rademikibart improved FEV1 by 130 mL versus placebo.
• The miss triggered a sharp reassessment of the drug’s prospects despite a broader September 17 market rally.
• No new company announcement dated September 17 was identified.